Severe Infection Outcomes With SGLT2 Versus DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Active-Comparator Meta-Analysis of Real-World Cohorts
Updated evidence clarifies how SGLT2 and DPP-4 inhibitors compare for infection risk, helping doctors choose safer diabetes medications for individual patients.
This updated systematic review searched four major databases through June 2026 to synthesize real-world evidence on severe infection outcomes comparing SGLT2 inhibitors to DPP-4 inhibitors in type 2 diabetes, applying methodological refinements to prior syntheses. The refined safety estimates are directly relevant to prescribing decisions for one of the most widely adopted drug classes in type 2 diabetes management.
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- Type 2 diabetes patients receiving SGLT2 inhibitors vs DPP-4 inhibitors
- Category
- Diagnostics
- Maturity
- Potentially Practice-Changing
- Journal
- Endocrinology, diabetes & metabolism
Why it surfaced
High-quality systematic review and meta-analysis of SGLT2i safety signals with updated evidence through 2026; directly informs prescribing for widely-used drug class in a globally prevalent disease.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.